65,437 trials
Chronic Obstructive Pulmonary Disease (COPD) · Chronic Bronchitis
Primary: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic — 0.019; -0.005 Litre — p=0.216
Relapsing Remitting Multiple Sclerosis
Primary: Urine Melatonin Levels — 19; 22; 925; 1,687 nanograms per gram of creatinine
Smoking Cessation · Marijuana Use
Primary: Number of Calls Completed — 123; 141 Total number of calls
Acute Myocardial Infarction · Coronary Artery Disease · Coronary Bypass Graft Stenosis of Autologous Vessel
Primary: High-Sensitivity Cardiac Troponin Levels From Days 0-7 — 29.2; 17.3; 23.2; 16.7 ng/mL (0-0.04) — p=0.05
Graft vs Host Disease · Congenital Aniridia · Chemical Burns
Primary: Safety and Tolerability: Number of Patients Experiencing a Device Related SAE (SADE) — 13; 0 Participants
Gestational Diabetes · Eye Diseases · Retinal Disease
Primary: Glucose Levels of the Groups in Pregnant Women With Impaired Blood Sugar and/or Gestational DM — 111.67; 154; 83.06; 88.15 mg/dl
Healthy
Primary: Part 1: Mass Balance and Recoveries of [14C] BI 1358894 Total Radioactivity in Urine and Faeces After Single Oral Dose (Fe0-tz) — 85.8 Percentage of administered dose
Amorphous, Eosinophilic, and Acellular Deposit · Constipation · Diarrhea
Primary: Assess Efficacy by Confirmed Overall Hematologic Response — 77.1 percentage of paticipants
Head Injury · Sport Injury
Primary: Number of Head Impacts — 100.24; 50.27 total number of practice impacts
Hypophosphatasia
Primary: Maximum Percent Change From Baseline in Extracellular Inorganic Pyrophosphate (PPi) — -36.46; -77.31; -56.88 percent change — p=0.0005
Kidney Transplantation
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0. — 2; 4; 7; 0 Participants
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants
Alcohol Use Disorder
Primary: Stimulant Effects of Alcohol When Co-administered With Drug or Matching Placebo — 28.23; 25.26; 20.57; 19.56 scores on scale
Cancer
Primary: Edmonton Symptom Assessment Scale Score (ESAS) — 9.6; 7.2 score on a scale
Kidney Transplant
Primary: Percent of Samples Successfully Returned for Drug Monitoring by Participants in the Unidirectional and Bidirectional Arms — 83; 100 % of samples postmarked with 48 hrs